Stifel sets USD 48.00 target for IDEAYA Biosciences stock
Published on 10/15/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Stifel set a USD 48.00 price target for IDEAYA Biosciences on October 13, 2026.
- IDEAYA Biosciences is scheduled to report third-quarter results on November 9, 2026.
- IDEAYA Biosciences stock costs EUR 30.04 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.
- IDEAYA Biosciences had a market capitalization of USD 3.3 billion as of October 15, 2026.
Stifel resumed coverage of IDEAYA Biosciences with a Buy rating and a USD 48.00 price target on October 13, 2026, according to Business Insider. Against the USD 33.72 Nasdaq quote dated October 15, 2026, that target is 42.35 percent higher. The stock was trading at EUR 30.04 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.
What the next report could add
IDEAYA Biosciences is scheduled to report third-quarter results on November 9, 2026, according to JrHisse. The calendar date gives investors the next defined checkpoint for the company, while the Stifel target puts the current market quotation in a wider valuation frame.
Stock position and trading range
The Nasdaq quote stood at USD 33.72 on October 15, 2026 at 2:57 p.m. EDT, with a market capitalization of USD 3.3 billion. IDEAYA Biosciences had a 52-week range of USD 26.81 to USD 42.68 on the same finance snapshot, placing the quote USD 8.96 below the high and USD 6.91 above the low.
The stock's reported price-to-earnings ratio was negative 17.36 as of October 15, 2026, while its dividend yield was 0.00 percent. The company is a biotechnology issuer listed on Nasdaq under the ticker IDYA.
Comparison with peers
IDEAYA Biosciences (NASDAQ, USD): P/E negative 17.36, market capitalization USD 3.3 billion
BioMarin Pharmaceutical (NASDAQ, USD): daily change plus 1.80 percent, P/E 144.21, market capitalization USD 10.9 billion
Immunocore (NASDAQ, USD): daily change plus 3.65 percent, P/E negative 154.28, market capitalization USD 1.5 billion
Price and investor perspective
The market data place IDEAYA between its 52-week boundaries, while the Stifel target remains materially above the latest Nasdaq quotation. The next scheduled reporting date is November 9, 2026.
The stock was trading at EUR 30.04 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of IDEAYA Biosciences stock.
IDEAYA Biosciences market data
- Company: IDEAYA Biosciences, Inc.
- ISIN: US45166A1025
- Ticker: IDYA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 8:49 p.m. CEST): EUR 30.04
- Market capitalization: USD 3.3 billion (as of October 15, 2026)
- 52-week range: USD 26.81-42.68 (as of October 15, 2026)
- Next earnings date: November 9, 2026
Market context: Market report S&P 500.
